If you backed Everest Medicines for its expanding Asia-Pacific footprint and kidney disease focus, the past twelve months have been bruising. For Everest Medicines shareholders, the loss over the past year was 43.8%, including dividends. If you had been weighing an entry in November 2025, analysts were projecting rapid revenue growth, rising margins and higher future P/E. What, exactly, did that bullish and bearish framework miss or underweight about how these drugs and deals would actually play out?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
This theme extends beyond Everest Medicines. See which of 123 healthcare AI stocks may still merit a closer look.
The Two Stories Investors Had To Choose Between On Everest Medicines
The shares cost HK$46.56 at the start of the period, and anyone looking at Everest Medicines had to choose between two very different but plausible stories.
The bullish narrative saw a Fair Value of HK$62.67, built on assumptions of 62.3% revenue growth and profit margins reaching 21.2%, supported by NEFECON and VELSIPITY rollouts as well as manufacturing localization.
The bearish case pointed to a HK$25.58 Fair Value, highlighting regulatory and Chinese pricing pressure, with concern that reliance on in-licensed assets and equity funding could keep dilution risk high.
What The Results Changed For Everest Medicines
Everest Medicines signed a global licensing deal for civorebrutinib outside parts of Asia, with up to about US$1.1b in potential milestones. This supported the optimistic focus on deals and kidney assets. Reported numbers added a twist. Revenue moved from CN¥446.1m in H1 2025 to CN¥1,147.8m in H1 2026 and the net loss narrowed sharply, yet profitability remained unproven with a net margin still at -0.5%. Overall, the evidence cut both ways.
The big assumption here was not just growth, but profitable growth. When you look at another biotech, check if rising sales are bringing the net margin meaningfully into positive territory and staying there, rather than relying only on milestone inflows or one period of sharply better losses.
What Everest Medicines' Lower Price Asks You To Believe Now
Everest Medicines now trades at HK$26.24, after the share price declined about 43.8% over the past year. The analyst consensus Narrative on Simply Wall St sees Fair Value above that level and leans on a multi-franchise renal, cardiovascular and ophthalmology platform rather than a single product bet.
For the fall to be an opportunity rather than a warning, a buyer would need to believe Everest Medicines can turn its renal and autoimmune focus around NEFECON into durable, diversified cash flows while managing China competition, supply execution and partner delivery on out-licensing deals.
"The main thing that has to go right is Everest Medicines successfully building a leading renal and autoimmune franchise around NEFECON and its broader nephrology portfolio, while managing competition and execution risks in China."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
Another Way To Play Kidney Risk
Everest Medicines asks you to judge one focused kidney pipeline. There is also room to look sideways at how chronic disease treatment is evolving elsewhere.
Kidney and autoimmune patients often live with overlapping heart, liver or infection risks. That same long arc of treatment need anchors a different pharmaceutical group.
This other business leans on vaccines and specialty drugs for long running conditions. Its researchers are pushing new cancer, liver and infectious disease therapies toward commercial use.
If more chronic patients receive earlier prevention and longer treatment, that could reshape where future cash flows pool in healthcare.
One Narrative has already put a figure on it. → Uncover the company trading 36% below one Narrative's Fair Value
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com